Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Immunicum AB (IMMU) Stock Price & Analysis

IMMU Stock Chart & Stats

SEK 5.43-SEK 0.07(-1.27%)
At close: 5:29 PM GMT+1
kr 5kr 6kr 710 Aug24 Aug7 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
SEK 5.01 - SEK 5.56
52-Week Range
SEK 3.86 - SEK 8.49
Previous Close
SEK 5.50
Volume
N/A
Average Volume (3M)
19.42K
Market Cap
SEK 348.89M
Enterprise Value
SEK 322.08M
Total Cash (Recent Filing)
SEK 59.88M
Total Debt (Recent Filing)
SEK 17.93M
Price to Earnings (P/E)
―
Beta
0.39
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.48
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage gives Immunicum greater financial flexibility than many early-stage biotech companies. Limited debt reduces interest and refinancing pressure, allowing more of its available capital to support clinical development and other strategic priorities.

Narrowing Losses

Narrower losses indicate some improvement in cost absorption and operating performance relative to the two prior reported periods. If maintained, this trend could extend the company’s funding runway and reduce the pace at which equity is consumed.

Improved Cash Burn Versus 2023

The material improvement in cash burn from 2023 suggests spending discipline has strengthened over time. While this does not yet create self-funding operations, a lower burn rate can preserve liquidity longer and provide more time for development progress.

Bears Say

No Recurring Revenue Base

Zero revenue across the latest TTM and two annual periods leaves the company without a consistent commercial funding base. Operations therefore remain dependent on external financing or collaboration-related payments rather than repeatable product sales.

Persistent Unprofitability

Persistent operating and net losses show that the current business does not yet cover its cost structure. Continued unprofitability can require additional funding, constrain investment choices, and increase the importance of successful clinical and commercial development.

Ongoing Cash Burn

Consistently negative operating and free cash flow means Immunicum is not generating the cash needed to fund operations internally. This creates continuing reliance on financing or other capital sources and leaves less financial resilience if development spending persists.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was kr 3.86 and its highest was kr 8.49 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is kr 348.89M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 8 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Aug 20, 2026. The company reported -kr 0.34 earnings per share for the quarter, beating the consensus estimate of -kr 0.45 by kr 0.11.
Is Immunicum AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate is -0.48.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 64,784,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -kr 0.34 in its last earnings report, beating expectations of -kr 0.45. Following the earnings report the stock price went down -0.149%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in SE:IMMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology